Toll Free: 1-888-928-9744

Meniere Disease - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Meniere Disease - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Meniere Disease - Pipeline Review, H1 2017, provides an overview of the Meniere Disease (Ear Nose Throat Disorders) pipeline landscape.

Meniere disease is a disorder of the inner ear that causes spontaneous episodes of vertigo. Signs and symptoms of Meniere disease are hearing loss, tinnitus and feeling of fullness in the ear. Causes include allergies, viral infection, head trauma and migraines. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Meniere Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meniere Disease (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Meniere Disease (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively.

Meniere Disease (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Meniere Disease (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Meniere Disease (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Meniere Disease (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Meniere Disease (Ear Nose Throat Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Meniere Disease (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Meniere Disease (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Meniere Disease - Overview Meniere Disease - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Meniere Disease - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Meniere Disease - Companies Involved in Therapeutics Development Orbis Biosciences Inc Otonomy Inc Quark Pharmaceuticals Inc Sound Pharmaceuticals Inc Synphora AB Meniere Disease - Drug Profiles betahistine dihydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress betamethasone valerate ER - Drug Profile Product Description Mechanism Of Action R&D Progress dexamethasone acetate SR - Drug Profile Product Description Mechanism Of Action R&D Progress latanoprost - Drug Profile Product Description Mechanism Of Action R&D Progress OR-105 - Drug Profile Product Description Mechanism Of Action R&D Progress QPHL-2 - Drug Profile Product Description Mechanism Of Action R&D Progress SPI-1005 - Drug Profile Product Description Mechanism Of Action R&D Progress Meniere Disease - Dormant Projects Meniere Disease - Product Development Milestones Featured News & Press Releases Feb 03, 2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere Disease and Vestibular Vertigo Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Meniere Disease Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In Meniere Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Meniere Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2017 Meniere Disease - Pipeline by Otonomy Inc, H1 2017 Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H1 2017 Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2017 Meniere Disease - Pipeline by Synphora AB, H1 2017 Meniere Disease - Dormant Projects, H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify